Roche purchases shares in tender offer for Spark Therapeutics, Inc.

Basel, 17 December 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) ( “Spark”) today announced that Roche’s wholly owned subsidiary 022019 Merger Subsidiary, Inc. has accepted for payment all shares validly tendered and not validly withdrawn pursuant to its tender offer for all outstanding shares of common stock of Spark, at a price of USD 114.50 per share in ca sh.  The tender offer expired at 5:00 p.m., New York City time, on 16 December 2019 and was not extended. Roche has been advised by Citibank, N.A., the depositary for the tender offer, that a total of approximately 23,276,342 shares of Spark ’s common stock were validly tendered and not validly withdrawn in the tender offer, which represent approximately 60.4% of the total number of shares of Spark’s common stock outstanding. Roche intends to complete the acquisition of Spark today through a merger of 022019 Merger Subsidiary, Inc. with and into Spark without a vote or meeting of Spark ’s shareholders. In the merger, all shares of Spark not owned by Spark, Roche or Roche’s wholly owned subsidiaries (other than shares as to which appraisal rights have been validly exercised under Delaware law) will be converted into the right to receive the same cash consideration per share, le ss any applicable withholding taxes, as was paid in the tender offer. Following completion of the merger, Spark will become a wholly owned subsidiary of Roche an...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news

Related Links:

Study Design. A retrospective study. Objective. To assess the long-term results of zero-profile spacer for 3-level anterior cervical discectomy and fusion (ACDF). Summary of Background Data. Although widely used, there are still controversies about the long-term results of zero-profile spacer, especially in multilevel cases. Methods. Cases received 3-level ACDF for cervical spondylotic myelopathy (CSM) using either zero-profile spacer (nā€Š=ā€Š27) (ZP Group), or plate and cages (nā€Š=ā€Š34) (PC Group), and with 5-year follow-up were reviewed. Neurological function and life quality were assessed by modified Japan...
Source: Spine - Category: Orthopaedics Tags: CERVICAL SPINE Source Type: research
Conclusion. In this consecutive case series we performed 231 ADRs in 147 patients in the outpatient setting, including multilevel and revision procedures, with 2 minor postoperative complications resulting in hospital unplanned admissions within 90 days. We believe that these procedures are safe to perform in an ASC. An efficient surgical team and careful patient selection criteria are critical in making this possible. Level of Evidence: 3
Source: Spine - Category: Orthopaedics Tags: CLINICAL CASE SERIES Source Type: research
Conclusion. Spinal infection in the presence of liver cirrhosis is challenging. The rate epidural abscess formation is relatively high. Early diagnosis remains the main cornerstone in the management and the indication for surgery should be carefully considered. Minimally invasive techniques should be used when possible to minimize complication rate, and higher amounts of intraoperative blood loss should be expected. Level of Evidence: 4
Source: Spine - Category: Orthopaedics Tags: CLINICAL CASE SERIES Source Type: research
A government report found medical facilities stretched to capacity and in need of everything from ventilators to thermometers. Prime Minister Boris Johnson of Britain was in the hospital. Iran moved to end a shutdown of businesses.
Source: NYT Health - Category: Consumer Health News Tags: Coronavirus (2019-nCoV) Hydroxychloroquine (Drug) Tests (Medical) Epidemics United States Politics and Government Unemployment Elizabeth II, Queen of Great Britain Johnson, Boris Trump, Donald J Fauci, Anthony S Source Type: news
This study aims to assess the impact of miR-149 rs2292832 C/T polymorphism and miR-149-5p expressions in cytotoxic effect of temozolomide against glioma cells. A total of 137 cases of glioma patients and 21 healthy cases were enrolled in this study for clinical research. We found that miR-149-5p was significantly downregulated in glioma cell lines and in blood leukocyte of glioma patients. Furthermore, miR-149 rs2292832 C/T polymorphism was significantly associated with glioma prognosis and temozolomide resistance. Subsequently, the glioma cell lines stable transfected with common miR-149 expression construct (miR-149-T) a...
Source: NeuroReport - Category: Neurology Tags: Integrative Systems Source Type: research
Source: BMJ News - Category: General Medicine Source Type: research
Spark will continue its operations in Philadelphia as an independent company within the Roche Group             Basel, 17 December 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) ( “Spark”) today announced the completion of the acquisition following the receipt of regulatory approval from all government authorities required by the merger agreement. Commenting on this important step forward, Severin Schwan, CEO of Roche, said, “We are excited about this important milestone because we believe that together...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
Basel, 16 December 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) ( “Spark”) today announced that the UK Competition and Markets Authority has unconditionally cleared Roche’s pending acquisition of Spark pursuant to its previously announced tender offer to purchase all of the outstanding shares of common stock (the “Shares”) of Spark for USD 114.50 per Sha re, net to the seller thereof in cash, without interest and subject to any withholding taxes required by applicable law and upon the terms and subject to the conditions set forth in the Offer to Purchas...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
Reena Goswami1, Gayatri Subramanian2, Liliya Silayeva1, Isabelle Newkirk1, Deborah Doctor1, Karan Chawla2, Saurabh Chattopadhyay2, Dhyan Chandra3, Nageswararao Chilukuri1 and Venkaiah Betapudi1,4* 1Neuroscience Branch, Research Division, United States Army Medical Research Institute of Chemical Defense, Aberdeen, MD, United States 2Department of Medical Microbiology and Immunology, University of Toledo College of Medicine and Life Sciences, Toledo, OH, United States 3Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States 4Department of Physiology and Biophysics, Case Western Reserve University, Clev...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
More News: Allergy & Immunology | Biotechnology | Blindness | Brain | Cancer | Cancer & Oncology | Children | Diabetes | Endocrinology | Gene Therapy | Genetics | Haemophilia | Hemophilia | Hospitals | Infectious Diseases | International Medicine & Public Health | Japan Health | Mergers and Aquisitions | Neurology | Neuroscience | Opthalmology | Palliative | Pharmaceuticals | Science | Switzerland Health | Tax | USA Health | WHO